Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00145249 · ClinicalTrials.gov registry record · Phase 2
Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT00145249 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 143 participants.
The verdict
NCT00145249, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
This study will examine the effectiveness and safety of a combination treatment for cryptococcal meningitis, a fungal infection common in persons with acquired immune deficiency syndrome (AIDS) in the developing world. The standard initial treatment includes two medications: amphotericin B for 2 weeks followed by 8 weeks of fluconazole. This study will look at whether study participants recover more quickly and have fewer side effects if they are given both drugs at the same time for 2 weeks followed by 8 weeks of fluconazole as compared to the standard treatment. Participants will be followed for approximately 6 months from the time they are enrolled into the study.
Interventions
- DRUG Fluconazole
- DRUG Amphotericin B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00145249
The ClinicalTrials.gov registry entry for NCT00145249 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluconazole is the first listed.
NCT00145249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00145249 about?
NCT00145249 is a clinical study titled "Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis". This study will examine the effectiveness and safety of a combination treatment for cryptococcal meningitis, a fungal infection common in persons with acquired immune deficiency syndrome (AIDS) in the developing world. The standard initial treatment includes two medications: amphotericin B for 2 wee...
What is the current status of trial NCT00145249?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2005-05. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00145249?
The interventions under investigation include: Fluconazole (DRUG), Amphotericin B (DRUG).
Who is sponsoring clinical trial NCT00145249?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.